Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

["Persistent" angina: rationale for a metabolic approach].

Mario Marzilli1

  • 1Cattedra di Cardiologia, Università degli Studi, Siena. marzilli@unisi.it

Italian Heart Journal : Official Journal of the Italian Federation of Cardiology
|April 13, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Great debate: preventive percutaneous coronary intervention added to optimal medical treatment should be the default treatment for non-flow-limiting vulnerable plaques.

European heart journal·2026
Same author

Early combination therapy with trimetazidine rapidly improves symptoms and quality of life in patients recently diagnosed with stable angina: The COMBINE angina study.

International journal of cardiology·2025
Same author

Myocardial Ischaemic Syndromes: Shifting from a Coronary-centric to a Substrate-based Nomenclature is More Accurate and Inclusive.

European cardiology·2025
Same author

Corrigendum to "HIV-Related Atherosclerosis: State-of-the-Art-Review" [Current Problems in Cardiology, Volume 48, Issue 9, September 2023, 101783].

Current problems in cardiology·2024
Same author

Myocardial Ischemic Syndromes: A New Nomenclature to Harmonize Evolving International Clinical Practice Guidelines.

Circulation·2024
Same author

Myocardial ischaemic syndromes: a new nomenclature to harmonize evolving international clinical practice guidelines.

European heart journal·2024

New metabolic agents like trimetazidine improve cardiac energy metabolism by promoting glucose oxidation. This offers clinical benefits for patients with ischemic heart disease, addressing a significant unmet need.

Area of Science:

  • Cardiology
  • Metabolic Medicine
  • Pharmacology

Context:

  • Ischemic heart disease presents significant mortality, morbidity, and economic burden.
  • Current management includes risk factor modification, patient education, and pharmacotherapy.
  • Patient profiles are evolving, with older patients and comorbidities like heart failure and diabetes.

Purpose:

  • To explore innovative therapeutic approaches for ischemic heart disease.
  • To investigate the role of cardiac energy metabolism in myocardial ischemia.
  • To evaluate the efficacy of metabolic agents in treating ischemic heart disease.

Summary:

  • Cardiac energy metabolism plays a crucial role in myocardial ischemia and reperfusion injury.
  • Optimizing cardiac energy metabolism involves promoting glucose oxidation over fatty acid oxidation.

Related Experiment Videos

  • 3-ketoacyl coenzyme A thiolase inhibitors (trimetazidine) partially inhibit fatty acid oxidation, increasing glucose and lactate combustion.

    • Impact:

    • Trimetazidine demonstrates clinical benefits in patients with ischemic heart disease.
    • This approach enhances cardiac function and protects against ischemia-reperfusion injury.
    • Offers a novel therapeutic strategy beyond traditional antianginal and secondary prevention drugs.